2006 OPEN FORUM Abstracts
Non Invasive Monitoring of Inflammation Markers in Exhaled Breath Condensate (EBC) in Patients with exacerbated COPD
G. Becher1), M.
Decker1), B. Timm-Labsch2), Elena Skrahina3),
Jantina Borkenhagen1), H. Knobloch1)
1)FILT Lungen- und Thoraxdiagnostik GmbH, Berlin, Germany, 2)Pneumol. Practice, Bernau, 3) Lung Clinic Minsk, Belorussia,
In Patients with COPD is a gap of objective criteria for treatment effects because of failure in improvement of pulmonary function. Exhaled markers in breath condensate could be suitable for detection of anti-inflammatory treatment (inflammometry). In Pneumologic practice this measurement is obviously essential for long and short term intervention in chronic lung inflammatory diseases.
Exhaled breath condensate was collected by ECoScreenT in patients with acute exacerbation of COPD at first visit and two weeks after onset of intervention. Intervention was a combination of inhaled glucocorticosteroides and antibiotics and theophyllin. Despite H2O2 in EBC were analysed off-line Nitrite; total protein and eNO. Traditional pulmonary function test (PFT) including Resistance, FEV1 and FVC was performed on each visit. H2O2 was measured by ECoCheckT a rapid point of care system for quantitative analyses.
Initial higher values of H2O2 were detected in patients with higher degree of COPD according to GOLD-staging. H2O2 was decreased for 70% of initial value after two week intervention. Values of H2O2 in light stages of disease were increased too, but not significant.
NO, Resistance and FEV1 did not show significant effects after two week intervention.
Table: H2O2-value due to staging of COPD (Mean ± SD)
|COPD||day 1||day 14|
|light||770 ± 750||480 ± 530 ns|
|severe||1240 ± 650||420 ± 350 s|
The measurement of H2O2 is a new non-invasive insight into the process of lung inflammation compared to traditional available function tests.
The nearly on-line measurement of H2O2 enabled the immediate decision for treatment and staging of inflammation. By easy to use analyses of further markers from EBC will be possible further staging of inflammation in chronic inflammatory airway diseases with no changes in PFT.